



Cyltezo® (adalimumab-adbm) and unbranded adalimumab-adbm – Clarification about formulary status

- On June 23, 2023, [OptumRx announced](#) beginning July 1, 2023 that its standard formulary would include three biosimilars at parity to [Humira® \(adalimumab\)](#):
 - [Hyrimoz® \(adalimumab-adaz\)](#) and [adalimumab-adaz](#) (low list) by Sandoz, both high concentration formulations
 - [Cyltezo® \(adalimumab-adbm\)](#) by Boehringer Ingelheim, the first interchangeable biosimilar and,
 - Amjevita™ (adalimumab-atto) ([high list](#) and [low list](#)) by Amgen, added earlier this year.
- On October 2, 2023, [Boehringer Ingelheim announced](#) the launch of [adalimumab-adbm](#), its low list biosimilar to Humira, also interchangeable.
 - Although a [Reuters article](#) stated that OptumRx has committed to covering the lower-cost version of Cyltezo on its formulary, OptumRx has not yet made a determination on standard formulary status for Boehringer Ingelheim's adalimumab-adbm.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.